https://www.selleckchem.com/products/cpi-1205.html
001). After a median follow-up of 50 months, underweight [HR 1.896, P=0.014] and overweight [HR 1.392, P=0.042] were associated with worse DFS. Obese patients had an increased risk of death [HR 1.653, P=0.032]. Normalweight men showed superior OS compared to underweight [HR 4.070, P=0.002], overweight [HR 2.077, P=0.010], severe overweight [HR 1.886, P=0.026] and obese [HR 2.046, P=0.015] men. Adding oxaliplatin to standard CRT significantly improved DFS in obese patients (P=0.034). In our study, underweight and overweight correlated w
Like
Comment
Share
